Our understanding of COVID-19 has evolved greatly since its first appearance in the U.S. in early 2020. Though our knowledge remains incomplete, we’ve learned a lot about the pathophysiology of the virus—especially its unique effects on the heart.
As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.
Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?
As many as 700 hearts from donors with hepatitis C are discarded each year in the U.S. New research suggests at least some of these organs may be suitable for transplant.
Even the best analytics won’t replace human interaction; protect your time with patients and colleagues. Focus on the patient-centered metrics, and try to be patient. It takes time to turn a mess into a masterpiece.
To get the operational perspective, CVB hosted a roundtable discussion with service line leaders about the opportunities and challenges they encounter around data.
Despite a steady stream of hype and "pockets" of change, most cardiologists aren’t seeing the transformation that Silicon Valley promised. ACC CIO John Rumsfeld, MD, PhD, explains what's missing and why engaging clinical partners could help.
In this first magazine of the 2020s, CVB invites the cardiology community to consider new mindsets for a number of areas, from treating dementias to tackling authorizations, documentation and collections.
In the debut of CVB's 2020 Vision series, healthcare administrators talk about the challenges they are facing as new financial realities descend on their patients and practices. It’s out with the old ways of tackling revenue cycle management. It’s time, they say, to adopt a mindset that safeguards patients' financial well-being while also furthering the organization's mission and protecting its margin.
